William Blair analyst Sami Corwin has maintained their bullish stance on KRYS stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sami Corwin’s rating is based on Krystal Biotech’s strong financial performance and strategic growth initiatives. The company reported a second-quarter revenue of $96.0 million, surpassing both the firm’s and consensus estimates, indicating robust growth driven by patient treatment restarts and an expanding sales team. Although a temporary dip in U.S. Vyjuvek revenue is anticipated in the third quarter, a rebound is expected in the fourth quarter, demonstrating resilience and potential for recovery.
Additionally, Krystal Biotech is making significant strides in securing reimbursement approvals, with over 575 approvals in the U.S., and aims to reach 720 by early 2026. The expansion of their sales team is expected to further boost patient starts and reimbursement rates. Furthermore, the company’s plans to launch Vyjuvek in key European markets, such as Germany and France, by 2025, highlight its commitment to international growth, supporting the Buy rating given by Sami Corwin.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $182.00 price target.